Latham-led Deal Shortlisted for the Scrip Awards’ Licensing Deal of the Year

Leading pharmaceutical intelligence and research company Citeline (formally Pharma Intelligence) has shortlisted the strategic global collaboration between GlaxoSmithKline plc (GSK) and Alector, Inc. in the Licensing Deal of the Year category as part of its prestigious Scrip Award program.

Our healthcare and life sciences team led by San Diego partner Steve Chinowsky, San Diego counsel Darryl Steensma, and London associate Oliver Mobasser represented GSK in the deal, which saw the multinational pharmaceutical company team up with Alector, a clinical stage biotechnology company pioneering a novel therapeutic approach for the treatment of neurodegenerative diseases called immuno-neurology, enter into a licensing agreement under which they will co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, which help combat a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease.

The awards recognize the very best innovations and achievements in global biopharma. The Licensing Deal of the Year category aims to celebrate creative and groundbreaking licensing agreements that help further the development and marketing of lifesaving drugs.